EMA (EU)
EVENT
Real-world data collection in Duchenne muscular dystrophy: Joint Heads of Medicines Agencies (HMA) / European Medicines Agency (EMA) multistakeholder workshop
Published: 9/25/2026Detected: 9/18/2026
Summary preview
Promotes structured collaboration to address gaps in real-world data (RWD) collection for Duchenne muscular dystrophy, with the goal of generating meaningful evidence on medicine effectiveness and safety.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountrare_diseases
pediatrics
neurology
clinical
safety
#real-world data
#RWD
#real-world evidence
#RWE
#Duchenne muscular dystrophy
Official Source Document Source Verified
Access the original document directly from EMA.
More from EMA (EU)
- Pharmacovigilance Risk Assessment Committee (PRAC): 23 - 26 November 202611/23/2026
- Seventeenth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines11/20/2026
- EMA annual call with General Practitioner Organisations' representatives11/20/2026
- Digitalisation and artificial intelligence in pharmaceutical manufacturing: Quality Innovation Group (QIG) - Follow-up roundtable meeting11/18/2026
- Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - November 202611/18/2026